All articles by
Adagio Medical to go public through $128m SPAC merger with ARYA
Adagio Medical will become a subsidiary of Aja Holdco, which will operate with its existing management team under the same name as Adagio Medical, and shares of the combined company will be listed on the Nasdaq Capital Market
FDA grants breakthrough status to Otsuka’s Sibeprenlimab for Berger’s disease
The breakthrough therapy status was based on the favourable results of the Phase 2 ENVISION clinical trial in which Sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo
US FDA approves Ipsen’s Onivyde regimen for metastatic pancreatic adenocarcinoma
The US FDA has approved Onivyde plus oxaliplatin, fluorouracil and leucovorin as a potential new standard-of-care first-line of treatment for mPDAC
Accelerated healing with NATROX® O₂: Managing Late Radiation Tissue Injury Post-Mohs Surgery
NATROX® Wound Care, a leading innovator in wound management solutions, is pleased to announce the publication of a groundbreaking study in WOUNDS journal, highlighting the potential of NATROX® O₂ in managing late radiation tissue injury following Mohs surgery.
Edgewise gets FDA Fast Track Designation for EDG-5506 to treat Duchenne
The FDA has also granted Rare Pediatric Disease Designation for the treatment of Duchenne, Fast Track designation for the treatment of Becker, and Orphan Drug Designation to EDG-5506
Accelerated healing with NATROX® O₂: Managing Late Radiation Tissue Injury Post-Mohs Surgery
NATROX® Wound Care, a leading innovator in wound management solutions, is pleased to announce the publication of a groundbreaking study in WOUNDS journal, highlighting the potential of NATROX® O₂ in managing late radiation tissue injury following Mohs surgery.
BioAge Announces $170m Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline
Takeda’s Eohilia gets FDA approval for eosinophilic esophagitis treatment
The FDA approval was based on efficacy and safety findings from two multicentre, randomised, double-blind, parallel-group, placebo-controlled 12-week studies
Biogen secures EC approval for Skyclarys to treat Friedreich’s ataxia
The EC approval was driven by the efficacy and safety data from the placebo-controlled MOXIe Part 2 study in which treatment with Skyclarys improved patient function compared to placebo
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)